Montelukast Therapy on Alzheimer's Disease

Condition:   Alzheimer Disease Interventions:   Drug: Montelukast;   Drug: Placebo oral tablet Sponsor:   Emory University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

In this study, we aimed to develop a risk prediction model to predict fast decline in the Aβ + MCI population using multimodal biomarkers. We included 186 Aβ + MCI patients who underwent florbetapir PET, brain MRI, cerebrospinal fluid (CSF) analyses, and FDG PET at baseline. We defined conversion to dementia within 3 years (= fast decline) as the outcome. The associations of potential covariates (MCI stage, APOE4 genotype, corrected hippocampal volume (HV), FDG PET SUVR, AV45 PET SUVR, CSF Aβ, total tau (t-tau), and phosphorylated tau (p-tau)) with the outcome were tested and nomograms were constru...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
Publication date: Available online 19 July 2019Source: Clinica Chimica ActaAuthor(s): Giulia Bivona, Bruna Lo Sasso, Giorgia Iacolino, Caterina Maria Gambino, Concetta Scazzone, Luisa Agnello, Marcello CiaccioAbstractThe current review provides an overview on the development of 25(OH)D measurement standardization tools over the last three decades and clarifies whether there is a role as a serum biomarker for vitamin D in neurological diseases. In the past, a lack of internationally recognized 25(OH)D reference measurement procedures and reference standard materials led to unstandardized serum total 25(OH)D results among re...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
In this study, to identify the differentially gut-liver-brain axis among APP/PS1 mice, FSS-treated APP/PS1 mice, and control mice, behavioral tests were performed to assess the cognitive ability and hematoxylin-eosin staining was used to assess neuronal damage in the hippocampus; immunohistochemistry, western blotting, a quantitative chromogenic end-point Tachypleus amebocyte lysate (TAL) assay kit, Malondialdehyde (MDA) assay kit, AP Assay Kit, and real-time quantitative PCR (qPCR) were used to assess the level of LPS, MDA, AP, and gut bacteria. We found that FSS regulates gut-liver-brain axis to regulate AP and gut bacte...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
The objective of the study was to understand respondents' willingness to accept hypothetical treatment-related risks in return for the benefit of additional time with normal memory from potential Alzheimer's disease interception therapies.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
Authors: Mydlikowska-Śmigórska A, Śmigórski K, Rymaszewska J Abstract Changes in the olfactory ability are one of early symptoms of developing neurodegenerative diseases, especially Parkinson's disease and Alzheimer's disease. In a healthy population olfactory function is characterized by independence from an intelligence quotient and various cognitive functions, e.g., memory. The peak of the olfactory ability falls between 20 and 40 years of age. In the geriatric population the worsening of the olfactory ability is found. Because of it, the knowledge on differences between the changes associated wi...
Source: Psychiatria Polska - Category: Psychiatry Tags: Psychiatr Pol Source Type: research
With the continued failure of clinical trials of therapies for Alzheimer's disease, largely immunotherapies, that aim to clear amyloid-β, a growing faction of researchers are rejecting the amyloid hypothesis. In that mainstream view of the condition, the accumulation of amyloid-β causes the early stages of Alzheimer's, but in addition to disrupting the function of neurons, it also causes immune cells in the brain to become inflammatory, dysfunctional, and senescent. This in turn sets the stage for the aggregation of tau protein into neurofibrillary tangles, which causes widespread cell death and the much more sev...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
A study by the University of California, Riverside, found children and teenagers who carry a variation of the APOE gene score worse on IQ tests by an average of 1.91 points.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Publication date: Available online 18 July 2019Source: Nitric OxideAuthor(s): Xiaoyi Tang, Zhuang Li, Weiwei Zhang, Zhongxiang YaoAbstractAlzheimer's disease (AD) is a typical neurodegenerative disease in central nervous system (CNS). Generally speaking, patients with severe AD are often accompanied with cognitive impairment. Oligodendrocytes (OLs) are myelin-forming cells in CNS, and myelin injury potentially has something to do with the cognitive impairment in AD. Based on the previous experimental studies, it has been recognized that nitric oxide (NO), as a signaling molecule, might have an influence on the axon and mye...
Source: Nitric Oxide - Category: Chemistry Source Type: research
Increased Neuronal Nuclear and Perikaryal Size in the Medial Mamillary Nucleus of Vascular Dementia and Alzheimer's Disease Patients: Relation to Nuclear Estrogen Receptor α. Dement Geriatr Cogn Disord. 2019 Jul 18;:1-7 Authors: Ishunina TA, Bogolepova IN, Swaab DF Abstract BACKGROUND: The hypothalamic medial mamillary (MMN) and the tuberomamillary (TMN) nuclei are important hubs in memory circuits. Previous studies determining the neuronal Golgi complex size showed decreased metabolic activity of the TMN neurons in both Alzhei-mer's disease (AD) and vascular dementia (VD), and no obvious decline...
Source: Dementia and Geriatric Cognitive Disorders - Category: Psychiatry Tags: Dement Geriatr Cogn Disord Source Type: research
In this study, we verify the impact of CDIP parameters compliance on total brain volume variance using 86 scans of the same individual acquired on various scanners. Data included planned data collection acquired within the Consortium pour l'identification précoce de la maladie Alzheimer - Québec (CIMA-Q) and Canadian Consortium on Neurodegeneration in Aging (CCNA) studies, as well as opportunistic data collection from various protocols. For images acquired from Philips scanners, lower variance in brain volumes were observed when the stated CDIP resolution was set. For images acquired from GE scanners, lower v...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
More News: Alzheimer's | Research